o2h Ventures Limited, an investment firm based in Cambridge, UK, manages “the o2h therapeutics and AI S/EIS fund” which is Britain’s first ever EIS and/or SEIS investment fund backing early stage biotech therapeutic and related AI opportunities. The fund invests in British Biotech Therapeutics with a focus on innovations that larger pharmaceutical companies may want to acquire.
The team at o2h have access to the most exciting scientific ideas through its live working relationships fostered over many years working as a discovery services company.
Sunil Shah co-founded o2h Ventures Ltd with his brother Prashant Shah in the year 2018. o2h operate from their proprietary 2.7 acre The Mill SciTech Park where they are developing a unique model for incubating small life science companies.
The fund is structured to be S/EIS compliant providing generous income, Inheritance and capital gains tax breaks for UK tax payers. The fund is open and we on-boarding investors at www.o2hventures.com